The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| NeoSpect depreotide | CIS bio international | Radionuclide Imaging | 🇪🇺 EU 2000-11-29 | Order → |
| Hexavac diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis, hepatitis B (recombinant) and Haemophilus influenzae type b conjugate vaccine, adjuvanted | Sanofi Pasteur MSD, SNC | Hepatitis B; Tetanus; Immunization; Meningitis, Haemophilus; Whooping Cough; Poliomyelitis; Diphtheria | 🇪🇺 EU 2000-10-23 | Order → |
| Infanrix Hexa diphtheria (D), tetanus (T), pertussis (acellular, component) (Pa), hepatitis B (rDNA) (HBV), poliomyelitis (inactivated) (IPV) and Haemophilus influenzae type-b (Hib) conjugate vaccine (adsorbed) | GlaxoSmithKline Biologicals S.A. | Hepatitis B; Tetanus; Immunization; Meningitis, Haemophilus; Whooping Cough; Poliomyelitis; Diphtheria | 🇪🇺 EU 2000-10-23 | Order → |
| Infanrix Penta diphtheria (D), tetanus (T), pertussis (acellular, component) (Pa), hepatitis B (rDNA) (HBV), poliomyelitis (inactivated) (IPV) vaccine (adsorbed) | GlaxoSmithKline Biologicals S.A. | Hepatitis B; Tetanus; Immunization; Whooping Cough; Poliomyelitis; Diphtheria | 🇪🇺 EU 2000-10-23 | Order → |
| Agenerase amprenavir | Glaxo Group Ltd. | HIV Infections | 🇪🇺 EU 2000-10-20 | Order → |
| Actos pioglitazone | CHEPLAPHARM Arzneimittel GmbH | Diabetes Mellitus, Type 2 | 🇪🇺 EU 2000-10-13 | Order → |
| Glustin pioglitazone | Takeda Pharma A/S | Diabetes Mellitus, Type 2 | 🇪🇺 EU 2000-10-11 | Order → |
| Panretin alitretinoin | Eisai GmbH | Sarcoma, Kaposi | 🇪🇺 EU 2000-10-11 | Order → |
| Keppra levetiracetam | UCB Pharma SA | Epilepsy | 🇪🇺 EU 2000-09-29 | Order → |
| Herceptin trastuzumab | Roche Registration GmbH | Stomach Neoplasms; Breast Neoplasms | 🇪🇺 EU 2000-08-28 | Order → |
| Helixate NexGen octocog alfa | Bayer AG | Hemophilia A | 🇪🇺 EU 2000-08-04 | Order → |
| Hepacare hepatitis B surface antigens recombinant (S, pre-S1, pre-S2) adsorbed on aluminium hydroxide [produced on genetically engineered murine (C127I) cells] | Evans Vaccines Ltd. | Hepatitis B; Immunization | 🇪🇺 EU 2000-08-04 | Order → |
| Kogenate Bayer octocog alfa | Bayer AG | Hemophilia A | 🇪🇺 EU 2000-08-04 | Order → |
| NovoMix insulin aspart | Novo Nordisk A/S | Diabetes Mellitus | 🇪🇺 EU 2000-08-01 | Order → |
| DaTSCAN ioflupane (123l) | GE Healthcare B.V. | Tomography, Emission-Computed, Single-Photon; Lewy Body Disease; Parkinson Disease; Alzheimer Disease | 🇪🇺 EU 2000-07-27 | Order → |
| Visudyne verteporfin | CHEPLAPHARM Arzneimittel GmbH | Myopia, Degenerative; Macular Degeneration | 🇪🇺 EU 2000-07-27 | Order → |
| Myocet liposomal (previously Myocet) doxorubicin | CHEPLAPHARM Arzneimittel GmbH | Breast Neoplasms | 🇪🇺 EU 2000-07-13 | Order → |
| Avandia rosiglitazone | SmithKline Beecham Plc | Diabetes Mellitus, Type 2 | 🇪🇺 EU 2000-07-11 | Order → |
| Nyracta rosiglitazone | SmithKline Beecham Plc | Diabetes Mellitus, Type 2 | 🇪🇺 EU 2000-07-11 | Order → |
| Venvia rosiglitazone | SmithKline Beecham Plc | Diabetes Mellitus, Type 2 | 🇪🇺 EU 2000-07-11 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.